Guides for adjuvant treatment of colon cancer

Clinical and Translational Oncology

Volumn 8, Issue 2, 2006, Pages 98-102

  Aranda, E ^a   Abad, A ^b   Carrato, A ^c   Cervantes, A ^d   Tabernero, J ^e   Diaz Rubio E ^f  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Adjuvant chemotherapy; Colonic neoplasms; Oxaliplatin; Polychemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; OXALIPLATIN; UFT; 1 UFT PROTOCOL; 1-UFT PROTOCOL; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; FOLFOX PROTOCOL; PLATINUM COMPLEX; TEGAFUR; URACIL;

ADJUVANT THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTINUOUS INFUSION; DRUG INDICATION; DRUG INFUSION; HUMAN; LIFE EXPECTANCY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PRACTICE GUIDELINE; PROGNOSIS; RISK ASSESSMENT; SAFETY; UNSPECIFIED SIDE EFFECT; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ALGORITHM; COLORECTAL TUMOR; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; LYMPH NODE METASTASIS; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADENOCARCINOMA; ALGORITHMS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FLUOROURACIL; HUMANS; LEUCOVORIN; LYMPHATIC METASTASIS; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; TEGAFUR; URACIL;

EID: 33646849099     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-006-0165-y     Document Type: Article

References (21)

1. Sant M, Aareleid T, Berrino F, et al. EUROCARE-3: Survival of cancer patients diagnosed 1990-94-results and commentary. Ann Oncol. 2003;14Suppl 5:S61-118.
2. Andre T, Colin P, Louvet C, et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 56 weeks as adjuvant therapy in stage II and III colon cancer: Results of a randomized trial. J Clin Oncol. 2003;21(15):2896-903.
3. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343-51.
4. De Gramont A, Boni C, Navarro M, et al. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and III colon cancer: Efficacy results with a median follow-up of 4 years. Proc Am Soc Clin Oncol. 2005;25(16S):3501.
5. Wolmark N, Wieand S, Kuebler JP, et al. A phase III trial comparing FULV to FULV+oxaliplatin in stage II or III carcinoma of the colon: Results of NSABP Protocol C-07. Proc Am Soc Clin Oncol. 2005;23(16S):3500.
6. Sargent DJ, Wieand HS, Haller DG, et al. Diseasefree survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20.898 patients on 18 randomized trials. J Clin Oncol. 2005;23(34):8664-70.
7. Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan plu fluorouracil/ leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89805). Proc Am Soc Clin Oncol. 2004;23:3500.
8. Ychou M, Raoul JL, Douillard JY, et al. A phase III randomized trial of LV5FU2+CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord2/FFCD9802). Proc Am Soc Clin Oncol. 2005;23(16S):3502.
9. Van Cutsem E, Labianca R, Hossfeld D, et al. Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts) (PETACC-3). Proc Am Soc Clin Oncol. 2005;23(16S):LBA8.
10. Wolmark N, Wieand B, Lembersky B, et al. A phase III trial comparing oral UFT to FULV in stage II and III carcinoma of the colon: Results of NSABP Protocol C-06. Proc Am Soc Clin Oncol. 2004;23:3508.
11. Twelves C, Wong A, Nowacki MP, et al. Early safety findings from a phase III trial of capecitabine plus oxaliplatin (XELOX) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer. Proc Am Soc Clin Oncol. 2005;23(16S):3523.
12. Moertel CG, Fleming TR, Macdonald JS, et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol. 1995;15:2936-43.
13. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol. 1999;17:1356-63.
14. Taal BG, Van Tinteren H, Zoetmulder FAN on behalf of the NACCP group. Adjuvant 5FU plus levamisole in colonic or rectal cancer: Improved survival in stage II and III. Br J Cancer. 2001;85:1437-43.
15. Mamounas E, Wieand S, Wolmark N, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dikes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project Adjuvant Studies (C-01, C-02, C03, and C-04). J Clin Oncol. 1999;17:1349-55.
16. Gray RG, Barnwell J, Hills R, et al. QUASAR: A randomized study of adjuvant chemotherapy (CT) vs observation including 5238 colorectal cancer patients. Proc Am Soc Clin Oncol. 2004;22(14S):3501.
17. Hickish T, Boni C, Navarro M, et al. FOL-FOX4 as adjuvant treatment for stage II colon cancer (CC): Subpopulation data from the MOSAIC trial. Proc Am Soc Clin Oncol. 2004;23:5619.
18. Benson III AB, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22(16):3408-19.
19. Figueredo A, Charette ML, Maroun J, et al. Adjuvant therapy for stage II colon cancer: A systematic review from the cancer care Ontario program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol. 2004;22(16):3395-407.
20. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004;22:1797-806.
21. Abad A, Carrato A, Navarro M, et al. Two consecutive phase II trials of biweekly oxaliplatin plus weekly 48-hour continuous infusion of nonmodulated high dose 5-fluorouracil as first line treatment for advanced colorectal cancer. Clin Colorectal Cancer. 2005;4(6):384-9.